GERM vs. XPH

Last updated Apr 2, 2026

Compare and contrast key facts about Amplify Treatments, Testing and Advancements ETF (GERM) and SPDR S&P Pharmaceuticals ETF (XPH).

GERM and XPH are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. GERM is a passively managed fund by Amplify that tracks the performance of the Prime Treatments, Testing and Advancements Index. It was launched on Jun 17, 2020. XPH is a passively managed fund by State Street that tracks the performance of the S&P Pharmaceuticals Select Industry Index. It was launched on Jun 19, 2006. Both GERM and XPH are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.

Performance

GERM vs. XPH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amplify Treatments, Testing and Advancements ETF (GERM) and SPDR S&P Pharmaceuticals ETF (XPH). The values are adjusted to include any dividend payments, if applicable.

GERM vs. XPH - Yearly Performance Comparison

	2026 (YTD)	2025	2024
GERM Amplify Treatments, Testing and Advancements ETF	0.00%	0.00%	0.00%
XPH SPDR S&P Pharmaceuticals ETF	-2.19%	31.60%	0.00%

Returns By Period

GERM

• 1D: 0.00%
• 1M: 0.00%
• YTD: 0.00%
• 6M: 0.00%
• 1Y: 0.00%
• 3Y*: —
• 5Y*: —
• 10Y*: —

XPH

• 1D: 1.16%
• 1M: -4.82%
• YTD: -2.19%
• 6M: 13.09%
• 1Y: 30.74%
• 3Y*: 11.47%
• 5Y*: 3.03%
• 10Y*: 3.94%

*Multi-year figures are annualized to reflect compound growth (CAGR)

GERM vs. XPH - Expense Ratio Comparison

GERM has a 0.68% expense ratio, which is higher than XPH's 0.35% expense ratio.

GERM

Amplify Treatments, Testing and Advancements ETF

XPH

SPDR S&P Pharmaceuticals ETF

Return for Risk

GERM vs. XPH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XPH

XPH Risk / Return Rank: 66
XPH Sharpe Ratio Rank: 69
XPH Sortino Ratio Rank: 69
XPH Omega Ratio Rank: 59
XPH Calmar Ratio Rank: 72
XPH Martin Ratio Rank: 62

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GERM vs. XPH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Amplify Treatments, Testing and Advancements ETF (GERM) and SPDR S&P Pharmaceuticals ETF (XPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	GERM	XPH	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	1.28	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.15	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.18	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.38	—

Dividends

GERM vs. XPH - Dividend Comparison

GERM has not paid dividends to shareholders, while XPH's dividend yield for the trailing twelve months is around 0.68%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
GERM Amplify Treatments, Testing and Advancements ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
XPH SPDR S&P Pharmaceuticals ETF	0.68%	0.83%	1.58%	1.28%	1.64%	0.95%	0.47%	0.64%	0.65%	0.67%	0.63%	7.15%

Drawdowns

GERM vs. XPH - Drawdown Comparison

The maximum GERM drawdown since its inception was 0.00%, smaller than the maximum XPH drawdown of -48.03%. Use the drawdown chart below to compare losses from any high point for GERM and XPH.

Drawdown Indicators

	GERM	XPH	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-48.03%	+48.03%
Max Drawdown (1Y) Largest decline over 1 year	0.00%	-13.15%	+13.15%
Max Drawdown (5Y) Largest decline over 5 years	—	-31.63%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-35.97%	—
Current Drawdown Current decline from peak	0.00%	-6.21%	+6.21%
Average Drawdown Average peak-to-trough decline	0.00%	-17.37%	+17.37%
Ulcer Index Depth and duration of drawdowns from previous peaks	0.00%	3.96%	-3.96%

Volatility

GERM vs. XPH - Volatility Comparison

The current volatility for Amplify Treatments, Testing and Advancements ETF (GERM) is 0.00%, while SPDR S&P Pharmaceuticals ETF (XPH) has a volatility of 9.05%. This indicates that GERM experiences smaller price fluctuations and is considered to be less risky than XPH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GERM	XPH	Difference
Volatility (1M) Calculated over the trailing 1-month period	0.00%	9.05%	-9.05%
Volatility (6M) Calculated over the trailing 6-month period	0.00%	16.40%	-16.40%
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	24.50%	-24.50%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	20.57%	-20.57%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	22.22%	-22.22%